Inhalation Sciences Sweden Past Earnings Performance
Past criteria checks 0/6
Inhalation Sciences Sweden's earnings have been declining at an average annual rate of -17.9%, while the Life Sciences industry saw earnings growing at 30.7% annually. Revenues have been growing at an average rate of 14.2% per year.
Key information
-17.9%
Earnings growth rate
-13.0%
EPS growth rate
| Life Sciences Industry Growth | 31.8% |
| Revenue growth rate | 14.2% |
| Return on equity | -36.6% |
| Net Margin | -27.1% |
| Next Earnings Update | 28 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Inhalation Sciences Sweden makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18 | -5 | 11 | 7 |
| 30 Sep 23 | 17 | -5 | 11 | 7 |
| 30 Jun 23 | 15 | -7 | 11 | 8 |
| 31 Mar 23 | 13 | -11 | 13 | 8 |
| 31 Dec 22 | 12 | -12 | 13 | 9 |
| 30 Sep 22 | 12 | -14 | 14 | 10 |
| 30 Jun 22 | 12 | -15 | 14 | 10 |
| 31 Mar 22 | 9 | -17 | 12 | 10 |
| 31 Dec 21 | 9 | -17 | 12 | 10 |
| 30 Sep 21 | 7 | -18 | 12 | 10 |
| 30 Jun 21 | 6 | -16 | 9 | 8 |
| 31 Mar 21 | 7 | 6 | 9 | 8 |
| 31 Dec 20 | 10 | 10 | 8 | 7 |
| 30 Sep 20 | 12 | 12 | 8 | 7 |
| 30 Jun 20 | 14 | 12 | 9 | 7 |
| 31 Mar 20 | 14 | -1 | 8 | 5 |
| 31 Dec 19 | 9 | -4 | 8 | 6 |
| 30 Sep 19 | 9 | -3 | 4 | 10 |
| 30 Jun 19 | 8 | -3 | 5 | 8 |
| 31 Mar 19 | 6 | -11 | 8 | 8 |
| 31 Dec 18 | 5 | -12 | 10 | 6 |
| 30 Sep 18 | 5 | -12 | 16 | 0 |
| 30 Jun 18 | 6 | -10 | 16 | 0 |
| 31 Mar 18 | 7 | -9 | 14 | 0 |
| 31 Dec 17 | 8 | -6 | 13 | 0 |
| 30 Sep 17 | 6 | -7 | 12 | 0 |
| 30 Jun 17 | 6 | -7 | 11 | 0 |
| 31 Mar 17 | 8 | -6 | 12 | 0 |
| 31 Dec 16 | 10 | -5 | 13 | 0 |
| 31 Dec 15 | 10 | -3 | 12 | 0 |
Quality Earnings: ISAB is currently unprofitable.
Growing Profit Margin: ISAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISAB is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.
Accelerating Growth: Unable to compare ISAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISAB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (46.4%).
Return on Equity
High ROE: ISAB has a negative Return on Equity (-36.62%), as it is currently unprofitable.